Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content in patients with renal cell carcinoma

Cancer

Volumn 78, Issue 4, 1996, Pages 819-826

  Yokogi, Hiroyuki ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

cell proliferation; DNA content; flow cytometry; kidney neoplasm; prognosis; proliferation associated nuclear antigen p105; renal cell carcinoma; survival

Indexed keywords

CYCLINE; DNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; DNA CONTENT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PLOIDY; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; CARCINOMA, RENAL CELL; DIPLOIDY; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 0029757367     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960815)78:4<819::AID-CNCR19>3.0.CO;2-Y     Document Type: Article

References (37)

1. Skinner DG, Colvin RB, Vermillon CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma: a clinical and pathologic study of 309 cases. Cancer 1971; 28:1165-77.
2. Clevenger CV, Bauer KD, Epstein AL. A method for simultaneous nuclear immunofluorescence and DNA content quantitation using monoclonal antibodies and flow cytometry. Cytometry 1985;6:208-14.
3. Clevenger CV, Epstein AL. Modulation of the nuclear antigen p105 as a function of cell-cycle progression. J Cell Physiol 1987;130:336-43.
4. Clevenger CV, Epstein AL, Bauer KD. Quantitative analysis of a nuclear antigen in interphase and mitotic cells. Cytometry 1987;8:280-6.
5. Bauer KD, Clevenger CV, Endow RK, Murad T, Epstein AL, Scarpelli DG. Simultaneous nuclear antigen and DNA content quantitation using paraffin-embedded colonic tissue and multiparameter flow cytometry. Cancer Res 1986; 46:2428-34.
6. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101:297-301.
7. Fuhman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
8. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31;1333-5.
9. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
10. Tachibana M, Deguchi N, Baba S, Jitsukawa S, Hata M, Tazaki H. Bromodeoxyuridine and deoxyribonucleic acid bivariate analysis in human renal cell carcinoma: does flow cytometric determination predict malignant potential or prognosis of patients with renal cell carcinoma? Am J Clin Pathol 1992;97(Suppl 1):38S-47S.
11. Ljungberg B, Larsson P, Roos G, Stenling R, Wilson G. Cell kinetics of renal cell carcinoma studied with in vivo iododeoxyuridine incorporation and flow cytometry. J Urol 1994;151:1509-13.
12. Larsson P, Roos G, Stenling R, Ljungberg B. Proliferation of human renal cell carcinoma studied with in vivo iododeoxyuridine labeling and immunohistochemistry. Scand J Urol Nephrol 1994;29:30-6.
13. Papadopoulos I, Weichert-Jacobsen K, Sprenger E, Wacker HH. DNA content and the proliferation marker Ki-67 as prognostic indicators in renal cell carcinoma. Urol Int 1994;53:181-5.
14. Riese de W, Crabtree W, Allhoff E, Werner M, Liedke S, Lenis G, et al. Prognostic significance of Ki-67 immunostaining in nonmetastatic renal cell carcinoma. J Clin Oncol 1993; 11:1804-8.
15. Tanioka F, Hiroi M, Yamane T, Hara H. Proliferating cell nuclear antigen (PCNA), immunostaining and flow cytometric DNA analysis of renal cell carcinoma. Zentralbl Pathol 1993;139:185-93.
16. Delahunt B, Bethwaite PB, Nacey JN, Ribas J. Proliferating cell nuclear antigen (PCNA) expression as a prognostic indicator for renal cell carcinoma: comparison with tumour grade, mitotic index, and silver-staining nuclear organizer region numbers. J Pathol 1993;170:471-7.
17. Delahunt B, Ribas JL, Nacey JN, Bethwaite PB. Nuclear organizer regions and prognosis in renal cell carcinoma. J Pathol 1991;163:31-7.
18. Larsson P. Cell proliferation in renal cell carcinoma. Scand J Urol Nephrol 1994;165 (Suppl):3S-48S.
19. Larsson P, Roos G, Stenling R, Ljungberg B. Tumor-cell proliferation and prognosis in renal-cell carcinoma, Int J Cancer 1993;55:566-70.
20. Delahunt B, Bethwaite PB, Thornton A, Ribas JL. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling: correlation with clinical outcome. Cancer 1995;75:2714-9.
21. Clevenger CV, Epstein AL. Use of immunogold electron micro-scopy and monoclonal antibodies in the identification of nuclear substructures. J Histochem Cytochem 1984; 32:757-65.
22. Clevenger CV, Epstein AL. Identification of a nuclear protein component of interchromatin granules using a monoclonal antibody and immunogold electron microscopy. Exp Cell Res 1984;151:194-207.
23. Kiyabu MT, Bishop PC, Parker JW, Turner RR, Fitzgibbons PL. Smooth muscle tumors of the gastrointestinal tract: flow cytometric quantitation of DNA and nuclear antigen content and correlation with histologic grade. Am J Surg Pathol 1988;12:954-60.
24. Fitzgibbons PL, Appley AJ, Turner RR, Bishop PC, Parker JW, Breeze RE, et al. Flow cytometric analysis of pituitary tumors: correlation of nuclear antigen p105 and DNA content with clinical behavior. Cancer 1988;62:1556-60.
25. Appley AJ, Fitzgibbons PL, Chandrasoma PT, Hinton DR, Apuzzo MLJ. Multiparameter flow cytometric analysis of neoplasms of the central nervous system: correlation of nuclear antigen p105 and DNA content with clinical behavior. Neurosurgery 1990;27:83-96.
26. Fitzgibbons PL, Turner RR, Appley AJ, Bishop PC, Nichols PW, Epstein AL, et al. Flow cytometric DNA and nuclear antigen content in astrocytic neoplasms. Am J Clin Pathol 1988;89:640-4.
27. Ohyama S, Yonemura Y, Kimura H, Kosaka T, Miyazaki I, Sasaki T. Proliferation-associated nuclear antigen p105 as a marker for metastasis of human gastric cancer. J Cancer Res Clin Oncol 1991;117:583-6.
28. Yonemura Y, Ohyama S, Kimura H, Kamata T, Matsumoto H, Yamaguchi A, et al. The expression of proliferative-associated nuclear antigen p105 in gastric carcinoma. Cancer 1991;67:2523-8.
29. Kimura H, Yonemura Y, Epstein AL. Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content in advanced gastric cancers. Cancer 1991;68:2175-80.
30. Fu KK, Hammond E, Pajak TF, Clery M, Doggett RLS, Byhardt RW, et al. Flow cytometric quantification of the proliferation-associated nuclear antigen p105 and DNA content in advanced head & neck cancers: results of RTOG 91-08. Int J Radiat Oncol Biol Phys 1994;29:661-71.
31. Oka K, Nakano T, Arai T. Cytoplasmic p105 index is an accurate mitotic index, but is not related to prognosis in cervical carcinoma. Arch Pathol Lab Med 1994;118:506-9.
32. Rainwater LM, Hosaka Y, Farrow GM, Lieber MM. Well differentiated clear cell renal carcinomas: significance of nuclear deoxyribonucleic acid patterns studied by flow cytometry. J Urol 1987;137:15-20.
33. Grignon DJ, Ayala AG, El-Naggar A, Wishnow KI, Ro JY, Swanson DA, et al. Renal cell carcinoma: a clinicopathologic and DNA flow cytometric analysis of 103 cases. Cancer 1989;64:2133-40.
34. Ljungberg B, Stenling R, Roos G. DNA content and prognosis in renal cell carcinoma: a comparison between primary tumor and metastasis. Cancer 1986;57:2346-50.
35. Currin SM, Lee SE, Walther PJ. Flow cytometric assessment of deoxyribonucleic acid content in renal adenocarcinoma:does ploidy status enhance prognostic stratification over stage alone? J Urol 1990;143:458-63.
36. Lanigan D, McLean PA, Murphy DM, Donovan MG, Curran B, Leader M. Ploidy and prognosis in renal carcinoma. Br J Urol 1993;71:21-4.
37. Nakano E, Kondoh M, Okatani K, Seguchi T, Sugao H. Flow cytometric analysis of nuclear DNA content of renal cell carcinoma correlation with histologic and clinical features. Cancer 1993;72:1319-23.